News & Events
IFM’s Gary Glick Discusses Future of Innate Immunity in Nature Biotechnology
IFM Therapeutics CEO and Co-Founder, Gary Glick, was interviewed as part of a story on inflammasomes as a chronic disease driver in Nature Biotechnology. View the full story, "Novartis Trial Validates Inflammasome As Chronic Disease Driver", on Nature.
*Please note a subscription to Nature is required to view the full article.